Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.

Expert Opin Drug Saf. 2017 Jun 22. doi: 10.1080/14740338.2017.1346082. [Epub ahead of print]

PMID:
28641055
2.

Natalizumab in Multiple Sclerosis: Long-Term Management.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L.

Int J Mol Sci. 2017 Apr 29;18(5). pii: E940. doi: 10.3390/ijms18050940. Review.

3.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

PMID:
28440858
4.

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT.

Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.

PMID:
28290755
5.

Parametric method for the noise risk assessment of professional orchestral musicians.

Bo M, Clerico M, Pognant F.

Noise Health. 2016 Nov-Dec;18(85):319-328. doi: 10.4103/1463-1741.195797.

6.

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea.

Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, Durelli L, Clerico M.

J Vis Exp. 2016 Nov 9;(117). doi: 10.3791/54606.

PMID:
27911406
7.

Influence of cigarette smoking on ALS outcome: a population-based study.

Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Marinou K, Bottacchi E, Pisano F, Mora G, Mazzini L, Chiò A.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1229-1233. doi: 10.1136/jnnp-2016-313793. Epub 2016 Sep 21.

PMID:
27656044
8.

Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.

Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco GT; RIVER study group.

Expert Opin Drug Deliv. 2016 Jul;13(7):931-5. doi: 10.1517/17425247.2016.1148029. Epub 2016 Feb 24.

PMID:
26909646
9.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Aug;3(4):e273.

10.

Use of a checklist to improve pain control in hospitalized cancer patients: the 38Checkpain project.

Gentili M, Clerico M, Spizzichino M, Fanelli G.

Future Oncol. 2016 Jan;12(2):199-205. doi: 10.2217/fon.15.291. Epub 2015 Dec 8.

PMID:
26643066
11.

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Barbero P, Busso M, Tinivella M, Artusi CA, De Mercanti S, Cucci A, Veltri A, Avagnina P, Calvo A, Chio' A, Durelli L, Clerico M.

J Neurol. 2015 Dec;262(12):2662-7. doi: 10.1007/s00415-015-7894-1. Epub 2015 Sep 26.

PMID:
26410746
12.

Normal saline versus heparin solution to lock totally implanted venous access devices: Results from a multicenter randomized trial.

Dal Molin A, Clerico M, Baccini M, Guerretta L, Sartorello B, Rasero L.

Eur J Oncol Nurs. 2015 Dec;19(6):638-43. doi: 10.1016/j.ejon.2015.04.001. Epub 2015 Apr 29.

PMID:
25933709
13.

Therapeutic education to cancer patients: experiences of Italian nurses.

Prandi C, Garrino L, Clerico M, Sommovigo T, Vellone E, Alvaro R.

Prof Inferm. 2014 Oct-Dec;67(4):243-51. doi: 10.7429/pi.2014.674235.

PMID:
25837480
14.

Epigenetic therapy for Friedreich ataxia.

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR.

Ann Neurol. 2014 Oct;76(4):489-508. doi: 10.1002/ana.24260. Epub 2014 Sep 16.

15.

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M.

J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5.

16.

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, Cugnasco P, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Sideri R, Marinou K, Bottacchi E, Pisano F, Cantello R, Mazzini L, Mora G; Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis.

JAMA Neurol. 2014 Sep;71(9):1134-42. doi: 10.1001/jamaneurol.2014.1129.

17.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406
18.

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.

Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group.

BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7.

19.

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2.

Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, Silvennoinen O, Niccolai E, Amedei A, Ivaldi F, Clerico M, Contessa G, Uccelli A, Durelli L, Novelli F.

J Immunol. 2012 Feb 1;188(3):1011-8. doi: 10.4049/jimmunol.1004013. Epub 2012 Jan 4.

20.

The late complications of totally implantable central venous access ports: the results from an Italian multicenter prospective observation study.

Dal Molin A, Rasero L, Guerretta L, Perfetti E, Clerico M.

Eur J Oncol Nurs. 2011 Dec;15(5):377-81. doi: 10.1016/j.ejon.2010.11.007. Epub 2010 Dec 16.

PMID:
21167777

Supplemental Content

Loading ...
Support Center